Foundation to co-host event with Fleming Initiative on AMR

Antimicrobial resistance (AMR) has been recognised as a global health crisis for over a decade. While awareness and global action have grown, the threat that drug resistance poses to modern healthcare still looms large. Without significant change, AMR is set to cause sharp rises in preventable deaths from resistant infections over the next two decades, hitting low- and middle-income countries (LMICs) the hardest. However, with targeted action by the pharmaceutical industry, this trajectory can be changed and millions of lives can be saved. 

On 10 March 2026, the Access to Medicine Foundation and the Fleming Initiative will host an invitation-only forum in London, Turning the Tide on AMR: From Pledges to Progress, marking the launch of the fourth AMR Benchmark report, which will assess how major pharmaceutical players active in the AMR space are delivering on their responsibility to address drug resistance. 

Convening senior leaders across government, investment, industry and civil society, the event will provide a platform for attendees to revisit themes from the 2024 UN High-Level Meeting on AMR and discuss current challenges in pursuing these agreements. Additionally, attendees will learn how to leverage findings from the 2026 AMR Benchmark to form advantageous partnerships, seize opportunities and take targeted action to curb AMR. 

The event agenda will include: 

• Presentation on the 2026 AMR Benchmark – Overview of key takeaways and findings from the report 

• Investor panel – How investors can utilise insights and best practices highlighted in the Benchmark to engage with the industry 

• Government panel – Progress since the 2024 UN High-Level Meeting on AMR 

• Industry panel – Discussion on company performance in the 2026 AMR Benchmark and generic companies’ expanding role in tackling drug resistance

The Foundation’s work on AMR 

In 2017, the Foundation began tracking how pharmaceutical companies active in the antimicrobials space take action to combat drug resistance and ensure appropriate access to their products in LMICs. Through the AMR Benchmark and separate thematic studies, which delve deeper into topics covered in the Benchmark reports, the Foundation has become a go-to source of expertise on drug resistance, and how different stakeholders in global health can work together to mitigate the crisis.